Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors

Xenobiotica

Volumn 46, Issue 10, 2016, Pages 862-867

  Umehara, Ken Ichi ^a   Zollinger, Markus ^a   Kigondu, Elizabeth ^b   Witschi, Marc ^a   Juif, Claire ^a   Huth, Felix ^a   Schiller, Hilmar ^a   Chibale, Kelly ^b   Camenisch, Gian ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Butyrylcholinesterase; Eserine; Ethylenediaminetetraacetic acid; Fraction hydrolyzed; Relative activity factor; Tacrine

Indexed keywords

CARBOXYLESTERASE 1 INHIBITOR; CARBOXYLESTERASE 2 INHIBITOR; CLOPIDOGREL; EDETIC ACID; ESTERASE INHIBITOR; IRINOTECAN; PHYSOSTIGMINE; TACRINE; UNCLASSIFIED DRUG; CARBOXYLESTERASE; ENZYME INHIBITOR; ESTERASE;

ARTICLE; DRUG CLEARANCE; DRUG HYDROLYSIS; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; PHENOTYPE; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM;

CARBOXYLESTERASE; ENZYME INHIBITORS; ESTERASES; HUMANS; LIVER;

EID: 84958765332     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1133867     Document Type: Article

References (26)

1. J.Albertí, A.Martinet, S.Sentellas, M.Salvà (2010). Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 38:1202–10.
2. J.R.Atack, Q.S.Yu, T.T.Soncrant,. (1989). Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases. J Pharmacol Exp Ther 249:194–202.
3. S.Bencharit, C.L.Morton, J.L.Hyatt,. (2003). Crystal structure of human carboxylesterase 1 complexed with the Alzheimer’s drug tacrine: from binding promiscuity to selective inhibition. Chem Biol 10:341–9.
4. L.M.Berry, L.Wollenberg, Z.Zhao (2009). Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 3:70–7.
5. T.D.Bjornsson, J.T.Callaghan, H.J.Einolf,. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32.
6. J.Camps, J.Marsillach, J.Joven (2009). The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 46:83–106.
7. T.Fukami, T.Yokoi (2012). The emerging role of human esterases. Drug Metab Pharmacokinet 27:466–77.
8. M.C.Gonzalvo, F.Gil, A.F.Hernández,. (1997). Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105:169–79.
9. R.S.Holmes, M.W.Wright, S.J.Laulederkind,. (2010). Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 21:427–41.
10. R.Humerickhouse, K.Lohrbach, L.Li,. (2000). Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189–92.
11. O.Jbilo, C.F.Bartels, A.Chatonnet,. (1994). Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32:1445–57.
12. Y.Kobayashi, T.Fukami, R.Higuchi,. (2012). Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem Pharmacol 84:1196–206.
13. C.L.Kuo, B.N.La Du (1998). Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos 26:653–60.
14. S.C.Laizure, V.Herring, Z.Hu,. (2013). The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33:210–22.
15. B.Li, M.Sedlacek, I.Manoharan,. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
16. D.R.Liston, J.A.Nielsen, A.Villalobos,. (2004). Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol 486:9–17.
17. C.J.Ng, D.J.Wadleigh, A.Gangopadhyay,. (2001). Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–9.
18. B.W.Ogilvie, E.Usuki, P.Yerino, A.Parkinson (2008). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: A.D.Rodrigues, ed. Drug–drug interactions. 2nd ed. New York: Informa Healthcare, 231--358.
19. N.J.Proctor, G.T.Tucker, A.Rostami-Hodjegan (2004). Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151–78.
20. E.Reiner, E.Pavković, Z.Radić, V.Simeon (1993). Differentiation of esterases reacting with organophosphorus compounds. Chem Biol Interact 87:77–83.
21. Y.Sato, A.Miyashita, T.Iwatsubo, T.Usui (2012). Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos 40:902–6.
22. M.Shimizu, T.Fukami, M.Nakajima, T.Yokoi (2014). Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos 42:1103–9.
23. M.Tang, M.Mukundan, J.Yang,. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76.
24. J.Wang, E.T.Williams, J.Bourgea,. (2011). Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. Drug Metab Dispos 39:1329–33.
25. G.Xu, W.Zhang, M.K.Ma, H.L.McLeod (2002). Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605–11.
26. H.J.Zhu, X.Wang, B.E.Gawronski,. (2013). Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 344:665–72.